Trial reportJournal of diabetes investigation2019
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
Trial report in Journal of diabetes investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- A systematic review of outcomes measured in interventional trials in people with diabetic sensorimotor polyneuropathy.Diabetic medicine : a journal of the British Diabetic Association · 2025Pooled it
- Diabetic Neuropathy: a Critical, Narrative Review of Published Data from 2019.Current pain and headache reports · 2021Pooled it
- Evaluation of the effectiveness and safety of ONO-2910 for the treatment of diabetic polyneuropathy: An early Phase IIa, multicenter, randomized, placebo-controlled, double-blind study in Japanese patients.Journal of diabetes investigation · 2026Trial
- Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China.Diabetes · 2024Trial
- Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.Journal of diabetes investigation · 2019Trial
- Leaving no stone unturned from bench to bedside: Challenges and future perspectives in diabetic polyneuropathy.Journal of diabetes investigation · 2026Article
- Multi-scale In Silico and Biochemical Evaluation of Natural Bisbenzylisoquinoline Alkaloids as Aldose Reductase Inhibitors.The protein journal · 2026Article
- Electrophysiological diagnosis using the coefficient of variation of R-R intervals and a point-of-care nerve conduction device is highly correlated to the diagnosis of diabetic polyneuropathy using conventional electromyographs.Journal of diabetes investigation · 2026Article
- Immunological mechanisms and therapeutic advances in diabetic neuropathy.Journal of neurology · 2026Review
- Chronic hyperglycemia and cardiovascular dysfunction: an in-depth exploration of metabolic and cellular pathways in type 2 diabetes mellitus.Cardiovascular diabetology. Endocrinology reports · 2025Review
- Targeted single cell expression profiling identifies integrators of sleep and metabolic state.G3 (Bethesda, Md.) · 2025Article
- Alpha-Tocopherol-Loaded Liposomes Reduce High Glucose Induced Oxidative Stress in Schwann Cells: A Proof of Concept Study.Diabetes & metabolism journal · 2025Article
- In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases.Archives of toxicology · 2024Article
- Article
- A medical odyssey of a 72-year-old man with Charcot-Marie-Tooth disease type 2 newly diagnosed with biallelic variants in SORD gene causing sorbitol dehydrogenase deficiency.American journal of medical genetics. Part A · 2023Article
- Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy.Diabetes & metabolism journal · 2023Review
- Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.Pharmaceuticals (Basel, Switzerland) · 2022Review
- An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy.Journal of diabetes research · 2022Review
- Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?Current diabetes reviews · 2022Review
- Physiological and Pathological Roles of Aldose Reductase.Metabolites · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 1 country.
Funding
Abstract
AIMS/
introductionDiabetic polyneuropathy is one of the most frequent diabetic complications, and impairs patients' quality of life. We evaluated the efficacy and safety of ranirestat (40 mg/day) in patients with diabetic polyneuropathy. MATERIALS AND
methodsThis was a multicenter, placebo-controlled, randomized double-blind, parallel-group, phase III study in which 557 patients were randomly assigned to either the ranirestat or placebo group and assessed for 52 weeks. The co-primary end-points were the changes in tibial motor nerve conduction velocity and total modified Toronto Clinical Neuropathy Score as a measure of clinical symptoms.
resultsThere was a significant increase in tibial motor nerve conduction velocity in the ranirestat group compared with the placebo group. The difference between groups in the change at last observation was 0.52 m/s (P = 0.021). Increases in nerve conduction velocity in the ranirestat group were found not only in the tibial motor nerves, but also in the median motor nerves, proximal median sensory nerves and distal median sensory nerves. No significant differences in modified Toronto Clinical Neuropathy Score or safety parameters were found between the two groups.
conclusionsRanirestat (40 mg/day) was well tolerated and improved nerve conduction velocity. Regarding symptoms and signs, no detectable benefits over the placebo were observed in the ranirestat group during the 52 weeks of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.